Status:
COMPLETED
A Study of MK-2060 in Healthy Participants (MK-2060-016)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Venous Thrombosis
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.
Eligibility Criteria
Inclusion
- The key inclusion criteria include but are not limited to the following:
- Is in good health before randomization
- Has a body mass index (BMI) between ≥18 and ≤32 kg/m\^2, inclusive
Exclusion
- The key exclusion criteria include but are not limited to the following:
- Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- Has a history of cancer
Key Trial Info
Start Date :
October 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 18 2025
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT06582602
Start Date
October 15 2024
End Date
April 18 2025
Last Update
May 21 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Advanced Pharma CR, LLC ( Site 0002)
Miami, Florida, United States, 33147
2
Alliance for Multispecialty Research, LLC ( Site 0001)
Knoxville, Tennessee, United States, 37920